A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera (R)) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Sharman Jeff; Liberati Anna Marina; Silva Rodrigo Santucci; Aurer Igor; Robbins Jeffery; Rosenberg Julie Ann; Khan Tahira; Alcasid Ann

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera (R)) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

【24h】

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera (R)) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

机译：与先前未处理的CD20阳性，低肿瘤负荷滤泡淋巴瘤（LTB-FL）的受试者中受试者中受试者中的Rituximab参考产物（Mabthera（R））相比，对PF-05280586（潜在的Rituximab BioSimilar）的随机，双盲疗效和安全性研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
作者
Sharman Jeff; Liberati Anna Marina; Silva Rodrigo Santucci; Aurer Igor; Robbins Jeffery; Rosenberg Julie Ann; Khan Tahira; Alcasid Ann;
展开▼
作者单位

Willamette Valley Canc Inst &

Res Ctr Springfield OR USA;

AO Santa Maria Dept Hematol Terni Italy;

Inst Hemomed Oncol &

Hematol Sao Paulo Brazil;

Univ Hosp Ctr Zagreb Dept Internal Med Div Hematol Zagreb Croatia;

Pfizer Inc Groton CT 06340 USA;

Pfizer Inc Groton CT 06340 USA;

Pfizer Inc Groton CT 06340 USA;

Pfizer Inc New York NY USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献

1. A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera (R)) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL) [J] . Sharman Jeff, Liberati Anna Marina, Silva Rodrigo Santucci, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：与先前未处理的CD20阳性，低肿瘤负荷滤泡淋巴瘤（LTB-FL）的受试者中受试者中受试者中的Rituximab参考产物（Mabthera（R））相比，对PF-05280586（潜在的Rituximab BioSimilar）的随机，双盲疗效和安全性研究
2. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera (R)) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL) [J] . BioDrugs: Clinical immunotherapeutics, biopharmaceuticals, and gene therapy . 2020,第2期

机译：与先前未处理的CD20阳性，低肿瘤负荷滤泡淋巴瘤（LTB-）（LTB-）（LTB-）（LTB-）（LTB-）（LTB - FL）
3. Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study [J] . Ogura Michinori, Manuel Sancho Juan, Cho Seok-Goo, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：生物仿制性CT-P10对先前未处理低肿瘤负荷滤泡淋巴瘤（LTBFL）的患者Rituximab的疗效和安全性比较：随机期III研究
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Phase 1 studies comparing safety tolerability pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma [O] . Yuankai Shi, Qingyuan Zhang, Xiaohong Han, 2021

机译：第1期研究比较HLX01（Rituximab BioSimilar）的安全性耐受性药代动力学和药效学和药效学在中国CD20阳性B细胞淋巴瘤中的中国患者中引用Rituximab
6. Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis [O] . Gerd Burmester, Edit Drescher, Pawel Hrycaj, 2020

机译：校正：随机双盲研究的功效和安全结果将所提出的生物杀虫剂ABP 798与中等至重度类风湿性关节炎的受试者中的Rituximab参考产物进行比较

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera (R)) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

著录项

相似文献

相关主题

期刊订阅